about
Klotho in cardiovascular disease: Current and future perspectivesDiabetic kidney disease: from physiology to therapeuticsImplications of Klotho in vascular health and disease.Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.Inflammatory cytokines in diabetic nephropathy.Influence of Klotho gene polymorphisms on vascular gene expression and its relationship to cardiovascular disease.The role of inflammatory cytokines in diabetic nephropathy.Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study.Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease.Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.Inflammatory pathways.FGF23/Klotho axis: phosphorus, mineral metabolism and beyond.Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease.Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes.Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results.Anti-inflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study.[Fibroblast growth factor 23/Klotho system in the context of cardiovascular damage].Expression of FGF23/KLOTHO system in human vascular tissue.Herpes simplex virus as a sentinel lesion for cytomegalovirus infection.Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients.Reduced Klotho is associated with the presence and severity of coronary artery disease.High incidence of hiatal hernia in patients with end-stage renal diseaseHiatal hernia in predialysis patientsHemodialysis urea rebound and membrane biocompatibility: accuracy of Kt/V estimations[White coat arterial hypertension and blood pressure control cards]Urticarial anaphylactoid reaction following metoprololPTH decrease after radioiodine treatment in a patient with end-stage renal diseaseAndrogens for the treatment of anemia in peritoneal dialysis patientsErrors in the selection of dialysate concentrates cause severe metabolic acidosis during bicarbonate hemodialysisErythropoietin response is blunted in critically ill patientsAntibody level after hepatitis B vaccinationEffects of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysis patients[Paraquat poisoning: report of two cases and literature review][Hepatitis C virus pathogenic potential][Characteristics of the diabetic patients referred for the first time to the nephrologist]
P50
Q26775409-DCE11814-4B8E-4BBC-A375-2F0850976817Q27021392-4F778F7B-44CF-485F-92D2-58189C41993EQ34780123-05CA04A4-8019-4CCA-B01C-D0B1F0A8DC2EQ34787799-9F31B83E-CC46-4B2C-9A39-1166B3597BAAQ35133177-3060EED1-20C4-4BFE-8B49-D0B1D5CA0561Q36476878-96E02268-B549-4939-BA27-B8F6487B033AQ37078749-3E80FACE-9227-4E13-96AF-8EB52AB30DD5Q37378445-2539F58E-0391-4E84-BB5A-6DE738775E49Q37553481-19BD6E23-3650-4BAD-9328-BF12AC0C4B9CQ37871339-04F8E513-FE89-4519-BA23-E0E87288E349Q37887387-BEEBBA09-B917-4F0F-8592-F790C1B27A4EQ37987643-308FFFE8-F7E3-4397-9877-2F1B80E531E9Q38205525-81C7CA8B-8505-4802-88D5-EE71B5437345Q38680018-DCE2F68D-5222-4DA7-BDBB-1E9E2F77D29EQ42480950-965AAD1E-A7EC-488A-BDC7-66C2950AF32DQ42688333-B059A6DB-5B62-4C53-AAFE-28654B24499EQ44503036-13C5B1CB-967C-437A-8D02-15B75BD1B8FFQ44839652-A4E83646-9538-4019-A7AB-3E789C0F309FQ45763239-0C6F506D-26D1-40C6-8BFD-D9DED78640D4Q51610568-1172EF23-C1EC-4393-A0C7-7F06569C1F47Q54237788-669C9ED4-1C29-47B6-A04D-4D44C2E85B90Q71703209-033EF21B-4DB4-40CF-88A0-FE5B94DFD4D2Q71829795-61D58ACE-B2B7-4EC6-B0D6-1B5B7F127DA6Q73062883-EF545938-5420-4E38-A748-11C9B038B851Q73141520-EC6299DC-D0A5-4254-AA3E-48849ABD9F22Q73229848-EB0571CC-2C1E-4519-A031-6109CD6C164FQ73235644-2899C03D-E695-4C79-80B0-799A6175CF7FQ73389791-41A82D06-C5D6-4083-A1AA-A54050272AFDQ73678021-842CFD2B-678D-41C2-9AD8-21C6BFBDCF62Q73732762-18AD67E6-177A-4EDF-B351-CE78F71236E0Q73832435-97DBBE03-6DF9-47EC-9EB4-CD7C74101430Q73853475-F1CF17C8-A72E-408C-B0F1-1953659F8A15Q74341134-1F5126FD-F0E4-412B-BAB7-657BB7484E4FQ77437682-3D60E46C-8CFD-4B5C-A70B-5FB250EFD0ACQ80468828-BEE4E486-2DDA-4B17-BFB0-0A5524680294
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Carmen Mora-Fernández
@ast
Carmen Mora-Fernández
@en
Carmen Mora-Fernández
@es
Carmen Mora-Fernández
@nl
Carmen Mora-Fernández
@sl
type
label
Carmen Mora-Fernández
@ast
Carmen Mora-Fernández
@en
Carmen Mora-Fernández
@es
Carmen Mora-Fernández
@nl
Carmen Mora-Fernández
@sl
prefLabel
Carmen Mora-Fernández
@ast
Carmen Mora-Fernández
@en
Carmen Mora-Fernández
@es
Carmen Mora-Fernández
@nl
Carmen Mora-Fernández
@sl
P106
P21
P31
P496
0000-0003-1570-6332